UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 12, 2010

PRESSURE BIOSCIENCES, INC.
(Exact Name of Registrant as Specified in its Charter)

MASSACHUSETTS
  (State or Other Jurisdiction of Incorporation)
 
  0-21615
  
  04-2652826
  (Commission File Number)
  
   (IRS Employer Identification No.)
 
  14 Norfolk Avenue, South Easton, MA
  
02375
(Address of Principal Executive Offices)
  
   (Zip Code)
 
(508) 230-1828 
(Registrant’s Telephone Number, Including Area Code)
 
 
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
 (d)           On July 12, 2010, based on the recommendation of the Nominating Committee, the Board of Directors unanimously elected Alan I. Goldberg to the Board of Directors, effective July 12, 2010, as a Class III Board member with a term expiring at the 2011 annual shareholder meeting.  This seat has been vacant since shareholders voted to amend the Company’s Articles of Incorporation and to divide the Board of Directors into three classes.
 
Mr. Goldberg has a degree in Finance from Northwestern University, and has spent his entire professional career in the worldwide commodities and finance communities.  He has been a broker, regional manager, and officer of a national brokerage firm; a long-term member of the Chicago Board of Trade; and chairman of a large investment fund.  He has served on private and public company boards, and is active in several educational and community charities.

Mr. Goldberg will receive the same cash compensation as other non-employee directors of the Company, which is a quarterly stipend of $2,500 to be accrued and not paid until such time in the future that the Board determines that the overall financial and cash position of the Company will allow payments of such amounts.

In the Company’s private placement of securities that closed in February 2009, Alan Goldberg purchased approximately $110,000 of units, with each unit consisting of one share of Series A Convertible Preferred Stock, and warrants to purchase shares of the Company’s common stock and shares of the Series A Convertible Preferred Stock.  For a more complete description of the private placement, see the Company’s Current Report on Form 8-K filed on February 18, 2009, which is incorporated herein by reference.
 
Item 9.01 Financial Statements and Exhibits.
 
(d)  Exhibits
 
Exhibit Number 
Exhibit Description    
99.1   
Press release dated July 12, 2010 of Pressure BioSciences, Inc. furnished herewith.
 
 
-2-
 
 
EXHIBIT INDEX
 
Exhibit Number 
Exhibit Description    
99.1   
Press release dated July 12, 2010 of Pressure BioSciences, Inc., furnished herewith.
 
 
-3-
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
     
Dated: July 12, 2010
PRESSURE BIOSCIENCES, INC.
     
 
By:  
/s/ Richard T. Schumacher
 
Richard T. Schumacher,
President and Chief Executive Officer
 
 
-4-